Pieris Pharmaceuticals Inc. (PIRS) NASDAQ
$11.40 (0.53) (-4.44%)
Market Cap: $1.18B
As of 04/25/24 09:53 AM EDT. Market open.
Pieris Pharmaceuticals Inc. (PIRS)
NASDAQ
$11.40
(0.53) (-4.44%)
Market Cap: $1.18B
As of 04/25/24 09:53 AM EDT. Market open.
Add to Portfolio
pieris pharmaceuticals is a clinical stage biotechnology company that discovers and develops anticalin-based drugs to target validated disease pathways in a unique and transformative way. our pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled anticalin to treat uncontrolled asthma and a half-life-optimized anticalin to treat anemia. proprietary ... read more
COMPANY PROFILE
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
CEO
Stephen Yoder
Full Time Employees
140
CEO Compensation (Base)
$500,000
CEO Compensation (Total)
$2.62M
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
CEO
Stephen Yoder
Full Time Employees
140
CEO Compensation (Base)
$500,000
CEO Compensation (Total)
$2.62M
URL
Address
255 State St Fl 9, Massachusetts, Boston, 02109-2615.
PRICE CHART FOR PIERIS PHARMACEUTICALS INC
From:
To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
$11.38
Previous Close
$11.93
Days Range
$11.39 - $11.94
52 week range
$10.89 - $80.80
Volume
4,518
Avg. Volume (30 days)
9,643
Market Cap
$1.18B
Dividend Yield
-
P/E
(48.09)
Shares Outstanding
98,935,025
Open
$11.38
Previous Close
$11.93
Days Range
$11.39 - $11.94
52 week range
$10.89 - $80.80
Volume
4,518
Avg. Volume (30 days)
9,643
Market Cap
$1.18B
Dividend Yield
-
P/E
(48.09)
Shares Outstanding
98,935,025
FINANCIAL STATEMENTS FOR PIERIS PHARMACEUTICALS INC
LOADING...
INSIDER TRANSACTIONS FOR PIERIS PHARMACEUTICALS INC
Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
KIRITSY CHRISTOPHER P | Director | May 25, 2023 | Buy | $0.85 | 10,000 | 8,500 | 20,000 | May 30, 2023, 04:21 PM |
Demuth Tim | Chief Medical Officer | May 13, 2022 | Buy | $1.71 | 6,000 | 10,260 | 6,000 | May 16, 2022, 08:19 PM |
Olwill Shane | Chief Development Officer | Aug 30, 2021 | Option Exercise | $1.52 | 38,400 | 58,368 | 43,038 | Sep 01, 2021, 04:38 PM |
Olwill Shane | Chief Development Officer | Aug 30, 2021 | Sale | $5.11 | 38,400 | 196,380 | 33,838 | Sep 01, 2021, 04:38 PM |
Aquilo Capital Management, LLC | 10% Owner | Jul 21, 2020 | Sale | $2.95 | 1,900,000 | 5,605,000 | 3,675,530 | Jul 22, 2020, 06:15 PM |
BVF PARTNERS L P/IL | 10% Owner | Sep 06, 2019 | Sale | $4.50 | 50,000 | 224,970 | 2,385,055 | Sep 10, 2019, 06:00 PM |
KIRITSY CHRISTOPHER P | Director | Sep 14, 2018 | Buy | $5.11 | 5,000 | 25,525 | 10,000 | Sep 17, 2018, 05:42 PM |
GERAGHTY JAMES A | Director | May 15, 2018 | Buy | $5.75 | 10,000 | 57,500 | 20,000 | May 16, 2018, 09:08 AM |
ORBIMED ADVISORS LLC | 10% Owner | Apr 30, 2018 | Sale | $6.35 | 1,000,000 | 6,350,000 | 4,511,130 | May 02, 2018, 05:13 PM |
ORBIMED ADVISORS LLC | 10% Owner | Feb 13, 2018 | Option Exercise | $4.77 | 7,897 | 37,671 | 5,508,552 | Feb 15, 2018, 04:57 PM |
ORBIMED ADVISORS LLC | 10% Owner | Feb 13, 2018 | Sale | $8.98 | 7,897 | 70,915 | 5,500,730 | Feb 15, 2018, 04:57 PM |
ORBIMED ADVISORS LLC | 10% Owner | Jan 03, 2018 | Sale | $7.35 | 1,709,620 | 12,565,707 | 5,500,730 | Jan 04, 2018, 03:23 PM |
ORBIMED ADVISORS LLC | 10% Owner | Dec 18, 2017 | Option Exercise | $2.09 | 147,635 | 308,052 | 7,340,465 | Dec 20, 2017, 05:12 PM |
ORBIMED ADVISORS LLC | 10% Owner | Dec 18, 2017 | Sale | $5.70 | 147,635 | 841,519 | 7,194,222 | Dec 20, 2017, 05:12 PM |
GERAGHTY JAMES A | Director | Aug 17, 2017 | Buy | $4.82 | 10,000 | 48,200 | 10,000 | Aug 17, 2017, 07:20 PM |
Reine Allan | See Remarks | Aug 17, 2017 | Buy | $4.89 | 20,000 | 97,800 | 65,000 | Aug 17, 2017, 07:19 PM |
Reine Allan | See Remarks | Aug 16, 2017 | Buy | $4.79 | 45,000 | 215,550 | 45,000 | Aug 17, 2017, 07:19 PM |
KIRITSY CHRISTOPHER P | Director | Apr 21, 2017 | Option Exercise | $1.59 | 5,000 | 7,950 | 5,000 | May 09, 2017, 06:30 PM |
DEPTULA-HICKS DARLENE M | SVP, Chief Financial Officer | Jun 13, 2016 | Buy | $1.66 | 5,000 | 8,300 | 5,000 | Jun 15, 2016, 05:00 PM |
Yoder Stephen S. | President and CEO | Jun 13, 2016 | Buy | $1.68 | 6,000 | 10,080 | 6,000 | Jun 15, 2016, 05:00 PM |
Matis Louis | SVP, Chief Development Officer | Jun 14, 2016 | Buy | $1.71 | 7,915 | 13,535 | 10,000 | Jun 15, 2016, 05:00 PM |
Matis Louis | SVP, Chief Development Officer | Jun 13, 2016 | Buy | $1.68 | 2,085 | 3,503 | 2,085 | Jun 15, 2016, 05:00 PM |
ORBIMED ADVISORS LLC | Director | Jul 06, 2015 | Buy | $2.75 | 500,000 | 1,375,000 | 7,194,222 | Jul 08, 2015, 05:46 PM |
Khuong Chau Quang | Director | Jul 06, 2015 | Buy | $2.75 | 500,000 | 1,375,000 | 7,194,222 | Jul 08, 2015, 05:45 PM |
Load More Insider Transactions
Buy
Sale
Option Exercise
Owner | Relationship | Date | Value($) |
KIRITSY CHRISTOPHER P | Director | 05/25/2023 | 8,500 |
Demuth Tim | Chief Medical Officer | 05/13/2022 | 10,260 |
Olwill Shane | Chief Development Officer | 08/30/2021 | 58,368 |
Olwill Shane | Chief Development Officer | 08/30/2021 | 196,380 |
Aquilo Capital Management, LLC | 10% Owner | 07/21/2020 | 5,605,000 |
BVF PARTNERS L P/IL | 10% Owner | 09/06/2019 | 224,970 |
KIRITSY CHRISTOPHER P | Director | 09/14/2018 | 25,525 |
GERAGHTY JAMES A | Director | 05/15/2018 | 57,500 |
ORBIMED ADVISORS LLC | 10% Owner | 04/30/2018 | 6,350,000 |
ORBIMED ADVISORS LLC | 10% Owner | 02/13/2018 | 37,671 |
ORBIMED ADVISORS LLC | 10% Owner | 02/13/2018 | 70,915 |
ORBIMED ADVISORS LLC | 10% Owner | 01/03/2018 | 12,565,707 |
ORBIMED ADVISORS LLC | 10% Owner | 12/18/2017 | 308,052 |
ORBIMED ADVISORS LLC | 10% Owner | 12/18/2017 | 841,519 |
GERAGHTY JAMES A | Director | 08/17/2017 | 48,200 |
Reine Allan | See Remarks | 08/17/2017 | 97,800 |
Reine Allan | See Remarks | 08/16/2017 | 215,550 |
KIRITSY CHRISTOPHER P | Director | 04/21/2017 | 7,950 |
DEPTULA-HICKS DARLENE M | SVP, Chief Financial Officer | 06/13/2016 | 8,300 |
Yoder Stephen S. | President and CEO | 06/13/2016 | 10,080 |
Matis Louis | SVP, Chief Development Officer | 06/14/2016 | 13,535 |
Matis Louis | SVP, Chief Development Officer | 06/13/2016 | 3,503 |
ORBIMED ADVISORS LLC | Director | 07/06/2015 | 1,375,000 |
Khuong Chau Quang | Director | 07/06/2015 | 1,375,000 |
Load More Insider Transactions
CHANGE IN SHARES OUTSTANDING FOR PIERIS PHARMACEUTICALS INC
STOCK BUYBACKS FOR PIERIS PHARMACEUTICALS INC
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
Load More
Period of Report: 12/31/2023
10-K/10-Q Filings: View
Previous Period
% Change in Shares
Quarter
09/30/2023
0.13%
1Q
06/30/2023
12.70%
2Q
03/31/2023
32.82%
3Q
12/31/2022
32.95%
4Q
09/30/2022
33.04%
5Q
06/30/2022
33.53%
6Q
03/31/2022
34.28%
7Q
12/31/2021
37.22%
8Q
09/30/2021
46.13%
9Q
06/30/2021
59.89%
10Q
03/31/2021
75.81%
11Q
12/31/2020
76.76%
12Q
09/30/2020
82.14%
13Q
06/30/2020
88.99%
14Q
03/31/2020
79.27%
15Q
12/31/2019
86.45%
16Q
Load More
BUYBACK ANNOUNCEMENT(S) FOR PIERIS PHARMACEUTICALS INC
LOADING...